STTK
$5.95
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States.
Recent News
Why Shattuck Labs Stock Soared More Than 53% Higher This Week
Investors were pleased to hear that the company's lead pipeline drug is making tangible progress.
Why Shattuck Labs Stock Soared in December
Buttressed by a significant amount of fresh capital, the company is showing progress in the early development of its top investigational drug.
Several Insiders Invested In Shattuck Labs Flagging Positive News
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
Analyst Confidence Upbeat on Shattuck Labs (STTK) Amid SL-325 Progress and Earlier Q3 2025 Result
With strong three-month performance and significant upside potential, Shattuck Labs, Inc. (NASDAQ:STTK) secures a spot on our list of the 12 hot penny stocks to invest in right now. Highlighting the SL-325’s Phase 1 readout, expected in Q2 2026, H.C. Wainwright’s Joseph Pantginis reiterated a “Hold” rating on Shattuck Labs, Inc. (NASDAQ:STTK) on November 7, […]
Hedge funds own 27% of Shattuck Labs, Inc. (NASDAQ:STTK) shares but individual investors control 32% of the company
Key Insights Significant control over Shattuck Labs by individual investors implies that the general public has more...